« Reporting On The Benefit Of Antidepressants , UK | Main | FDA Approves Pristiq For The Treatment Of Adult Patients With Major Depressive Disorder »
DOV Pharmaceutical, Inc. Initiates Phase II Clinical Trial In Patients With Major Depressive Disorder
By Depressed Jane | February 29, 2008
DOV Pharmaceutical, Inc. (OTCBB: DOVP) announced that it has initiated a Phase II clinical trial of DOV 21,947 in patients diagnosed with major depressive disorder. DOV 21,947 is DOV’s lead triple reuptake inhibitor, or “TRIP,” for the treatment of depression and obesity. The clinical trial, which will randomize approximately 200 patients, is a double-blind, placebo-controlled, multi-center study assessing the efficacy and safety of DOV 21,947 over a six-week period.
Topics: A Depressed Life |